Recent advances in treatment approaches of mucopolysaccharidosis VI

Current Pharmaceutical Biotechnology

Volumn 12, Issue 6, 2011, Pages 956-962

  Giugliani, Roberto ^a,b,c   Carvalho, Clarissa Gutiérrez ^a,b   Herber, Silvani ^a,b   de Camargo Pinto, Louise Lapagesse ^a,d  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c INAGEMP National Institute of Population Medical Genetics   (Brazil)

^d UNIVERSITY OF CAXIAS DO SUL   (Brazil)

Author keywords

Enzyme replacement therapy; Glycosaminoglycans; Lysosomal storage diseases; Maroteaux Lamy syndrome; Mucopolysaccharidosis VI; Therapy of genetic disorders

Indexed keywords

DERMATAN SULFATE; GALSULFASE; GENISTEIN; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN DERMATAN SULFATE; INFLIXIMAB; LENTIVIRUS VECTOR; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT ENZYME; RECOMBINANT HUMAN ARYLSULFATASE B; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ARTICLE; BACTERIAL ENDOCARDITIS; BLOOD BRAIN BARRIER; BRAIN VENTRICLE PERITONEUM SHUNT; CAT; CELL LINEAGE; CHO CELL; CLINICAL TRIAL; CORNEA TRANSPLANTATION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYDROCEPHALUS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INTRACRANIAL PRESSURE; INTRAOCULAR PRESSURE; LONG TERM CARE; LUNG FUNCTION; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MEDICAL CARE; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; RISK ASSESSMENT; SPINAL CORD DECOMPRESSION; SUBSTRATE REDUCTION THERAPY; SURGICAL TECHNIQUE;

ANIMALS; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUCOPOLYSACCHARIDOSIS VI;

EID: 79956286308     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795542688     Document Type: Article

References (41)

1. Neufield, E.F.; Muenzer, J. In, The mucopolysaccharidoses. CR Scriver, A.L.; Beaudet, A.L.; Sly, W.S.; D Valle Eds., The metabolic and molecular bases of inherited disease, McGraw-Hill Medical, New York, 2001, pp. 3421-3452.
2. Meikle, P.J.; Hopwood, J.J.; Clague, A.E.; Carey, W.F. Prevalence of lysosomal storage disorders. JAMA, 1999, 281, 249-254.
3. Poorthuis, B.J.; Wevers, R.A.; Kleijer, W.J.; Groener, J.E.; Jong, J.G.; Weely, S.L. The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet., 1999, 105,151-156.
4. Coelho, J.C.; Wajner, M.; Burin, M.G.; Vargas, C.R.; Giugliani, R. Selective screening of 10.000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur. J. Pediatr., 1997, 156, 650-654.
5. Albano, L.M.; Sugayama, S.S.; Bertola, D.R.; Andrade, C.E.; Utagawa, C.Y.; Puppi, F.; Nader, H.B.; Toma, L.; Coelho, J.; Leistner, S. Clinical and laboratorial study of 19 cases of mucopolysaccharidoses. Rev. Hosp. Clin. Fac. Med. São Paulo, 2000, 55, 213-218.
6. Swiedler, S.J.; Beck, M.; Bajbouj, M.; Giugliani, R.; Schwartz, I.; Harmatz, P.; Wraith, J.E.; Roberts, J.; Ketteridge, D.; Hopwood, J.J. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am. J. Med. Genet., 2005, 134(2),144-150.
7. Valayannopoulos, V.; Nicely, H.; Harmatz, P. Mucopolysaccharidosis VI. Orphanet J. Rare Dis., 2010, 5, 5
8. Giugliani, R.; Harmatz, P.; Wraith, J.E. Management guidelines for mucopolysaccharidosis VI. Pediatrics, 2007, 120 (2), 405-418
9. Azevedo, A.C.; Schwartz, I.V.; Kalakun, L.; Brustolin, S.; Burin, M.G.; Beheregaray, A.P.; Leistner, S.; Giugliani, C.; Rosa, M.; Barrios, P. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin. Genet., 2004, 66, 208-213.
10. Civallero, G.; Michelin, K.; de M, J.; Viapiana, M.; Burin, M.; Coelho, J.C.; Giugliani, R. Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with se lected inherited lysosomal storage diseases. Clin. Chim. Acta, 2006, 372, 98-102
11. Pitz, S.; Ogun, O.; Arash, L.; Miebach, E.; Beck, M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch. Clin. Exp. Ophtalmol., 2009, 247, 975-980.
12. Naumann, G.O.; Rummelt, V.; Clearing of the para-transplant host cornea afterperforating keratoplasty in Maroteaux-Lamy syndrome (type VI-A Mucopolysaccharidosis)]. Klin Monbl. Augenheilkd, 1993, 203(5),351-360.
13. Wynn, R.F.; Wraith, J.E.; Meara, J.A.; Tylee, K.; Thornley, M.; Church, H.J.; Bigger, A.B. Improved metabolic corretion in patiens with lysosomal storage disease treated with hematopoietic atem cell transplant compared with enzyme replacement therapy. J. Pediatr, 2009,154, 609-611
14. Krivit, W.; Peters, C.; Shapiro, E. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol., 1999, 12, 167-176.
15. Peters C.; Steward, C. Hematopoietic cell transplantation for inherited metabolic diseases, an overview of outcomes and practice guidelines. Bone Marrow Transplant., 2003, 31, 229-239
16. Lange, M.C.; Teive, H.A.; Troiano, A.R; Bitencourt, M.; Funke,V.A. Bone marrow transplantation in patients wiith storage diseases, a developing country experience. Arq. Neuropsiquiatr, 2006, 64, 1-4.
17. Summers, C.; Purple, R.; Krivit, W. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation, a preliminary report. Ophthalmology, 1989, 96, 977-985.
18. Wang, C.C.; Hwu, W.L.; Lin, K.H. Long-term follow-up of a girls with Maroteaux-Lamy syndrome after bone marrow transplantation. World J. Pediatr, 2001, 4, 234-237
19. Harmatz, P.; Whitley, C.B.; Waber, L.; Pais, R.; Steiner, R.; Plecko, B.; Kaplan, P.; Simon, J.; Butensky, E.; Hopwood, J.J. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteux-Lamy syndrome). J. Pediatrics, 2004, 144, 574-580.
20. White J.T.; Martell, L.A.; Van Tuyl, A.; Boyer, R.; Warness, L.; Taniguchi, G.T.; Foehr, E. Development, validation, and clinical implementation of an assay to measure total antibody response to Naglazyme® (Galsulfase). AAPS J., 2008, 10 (2), 363-372
21. Crawley AC, Brooks DA, Muller VJ, Petersen BA, Isaac EL, Bielicki J, King BM, Boulter CD, Moore AJ, Fazzalari NL, Anson DS, Byers S, Hopwood JJ. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest., 1997, 97(8),1864-1873.
22. Harmatz, P.; Giugliani, R.; Schwartz, I.; Guffon, N.; Teles, E.L.; Miranda, M.C.S.; Wraith, J.E.; Beck, M.; Arash, L.; Scarpa, M.; Yu, Z.; Wittes, J.; Berger, K.I.; Newman, M.S.; Lowe, A.M.; Kakkis, E.; Swiedler, S.J. Enzyme replacement therapy for mucopolysaccharidosis VI, a phase 3, randomized, double-blind, placebocontrolled, multinational study of recombinant human Nacetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open label extension study. J. Pediatrics, 2006, 148, 533-539e.5
23. Harmatz, P.; Ketteridge, D.; Giugliani, R.; Guffon, N.; Teles, E.L.; Miranda, M.C.S.; Yu, Z.; Swiedler, S.J.; Hopwood, J.J. Direct comparison of measures of endurance, mobility, and joint function during enzyme replacement therapy of mucopolisaccharidosis VI (Maroteaux-Lamy syndrome), results after 48 weeks in a phase 2 open-label clinical study of recombinant human Nacetylgalactosamine 4-sulfatase. Pediatrics, 2005, 115 (6), e681-e689
24. Harmatz, P.; Giugliani, R.; Schwartz, I.V.D.; Guffon, N.; Teles, E.L.; Miranda, M.C.S.; Wraith, J.E.; Beck, M.; Arash, L.; Scarpa, M.; Ketteridge, D.; Hopwood, J.J.; Plecko, B.; Steiner, R.; Whitley, C.B.; Kaplan, P.; Yu, Z.; Swiedler, S.J.; Decker, C. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI, final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Gene. Metabol., 2008, 94, 469-475.
25. El Dib, R.P.; Pastores, G.M. A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), focus on galsulfase. Biolog. Targets Ther., 2009, 3, 459-468.
26. Harmatz, P.; Yu, Z.; Giugliani, R.; Schwartz, I.V.D.; Guffon, N.; Teles, E.L.; Miranda, M.C.S.; Wraith, J.E.; Beck, M.; Arash, L.; Scarpa, M.; Ketteridge, D.; Hopwood, J.J.; Plecko, B.; Steiner, R.; Whitley, C.B.; Kaplan, P.; Swiedler, S.J.; Hardy, K.; Berger, K.I.; Decker, C. Enzyme replacement therapy for mucopolysaccharidosis VI, evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J. Inherited Metabol. Dis., 2010, 33(1), 51-60
27. Scarpa, M.; Barone, R.; Fiumara, A.; Astarita, L.; Parenti, G.; Rampazzo, A.; Sala, S.; Sorge, G.; Parini, R. Mucopolysaccharidosis VI, the Italian experience. Eur. J. Pediatrics, 2009, 168, 1203-1206.
28. Auclair D, Hopwood JJ, Brooks DA, Lemont JF, Crawley AC. Replacement therapy in mucoplysaccharidosis type VI, advantages of early onset of therapy. Mol. Gen. Metabol., 78, 2003, 163-174
29. Pitz, S.; Ogun, O.; Arash, L.; Miebach, E.; Beck, M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch. Clin. Exp. Ophtalmol., 2009, 247, 975-980.
30. Wraith, J.E. Limitations of enzyme replacement therapy, current and future. J. Inherited Metabol. Dis., 2006, 29, 442-447.
31. Schlander, M.; Beck, M. Expensive drugs for rare disorders, to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr. Med. Res. Opin., 2009, 25(5), 1285-1293.
32. Auclair, D.; Finnie, J.; White, J.; Nielsen, T.; Fuller, M.; Kakkis, E.; Cheng, A.; O'Neil, C.A.; Hopwood, J.J. Repeated intrathecal injections of recombinant human-4-sulphatase remove dural storage in mature mucopplysaccharidosis VI cats primed with a shortcourse tolerisation regimen. Mol. Genet. Metabol., 2010, 99, 132-141
33. Muñoz-Rojas, M.V.; Horovitz, D.D.G.; Jardim, L.B.; Raymundo, M.; Llerena Jr., J.C.; de Magalhães, T.S.C.P.; Vieira, T.A.; Costa, R.; Kakkis, E.; Giugliani, R. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol. Genet. Metabol., 2010, 99(4), 346-350.
34. Auclair, D.; Hopwood, J.J.; Lemontt, J.F.; Chen, L.; Byers, S. Long-term intra-articular administration of recombinant human Nacetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI. Mol. Gene. Metabol., 2007, 91, 352-361.
35. McGill, J.J.; Inwood, A.C.; Coman, D.J.; Lipke, M.L.; de Lore, D.; Swiedler, S.J.; Hopwood, J.J. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age -a sibling control study. Clin. Genetics, 2009, 77(5),492-498
36. Piotrowska, E.; Jakóbkiewicz-Banecka, J.; Baranska, S.; Tylki-Szymanska, A.; Czartoryska, B.; Wegrzyn, A.; Wegrzyn, G. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidosis. Eur. J. Hum. Genet., 2006, 14, 846-852.
37. Simonaro, C.; Ge, Y.; Eliyahu, E.; He, K.; Jepsen, K.; Schuchman, E. Involvement of the toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. USA, 2010, 107, 1 222-1227
38. Yogalingan, G.; Muller, V.; Hopwood, J.J.; Anson, D.S. Regulation of N-acetylgalactosamine 4- sulfatase expression in retrovirus transduced feline mucopolysaccharidosis type VI muscle cells. DNA Cell. Biol., 1999, 18, 187-195
39. Tessitore, A.; Faella, A.; ÓMalley, T.; Cotugno, G.; Doria, M.; Kunieda, T.; Matarese, G.; Haskins, M.; Auricchio, A. Biochemical, pathological and skeletal improvement of mucopolysacharidosis VI after gene transfer to liver but not to muscle. Mol. Ther., 2008, 16(1), 30-37
40. Byers, S.; Rothe, M.; Lalic, J.; Koldej, R.; Ansons, D.S. Lentivitalmediated correction of MPS VI cells and gene transfers to joint tissues. Mol. Genet. Metabol., 97 2009, 102-109
41. Alessandra Tessitore, Marinella Pirozzi1, Alberto Auricchio Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. Pathogenetics, 2009, 2(1), 41-52